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hereditary angioedema. Twenty-one articles described barriers to long-term prophylaxis with intravenous human C1-
esterase inhibitor (C1-INH) due to challenges with life-long vascular access and attack risk.
What does this article add to our knowledge? The long-term Clinical Study for Optimal Management of Preventing
Angioedema with Low-Volume Subcutaneous C1-Inhibitor Replacement Therapy (COMPACT) demonstrates that
continuous replacement therapy with subcutaneous C1-INH provides sustained treatment effectiveness with minimal
adverse effects.
How does this study impact current management guidelines? This study confirms previous recommendations for
subcutaneous C1-INH replacement as a safe and effective long-term prophylaxis against symptoms, attacks, and need for
rescue therapy in hereditary angioedema.BACKGROUND: For the prevention of attacks of hereditary
angioedema (HAE), the efficacy and safety of subcutaneous
human C1-esterase inhibitor (C1-INH[SC]; HAEGARDA, CSL
Behring) was established in the 16-week Clinical Study for
Optimal Management of Preventing Angioedema with Low-
Volume Subcutaneous C1-Inhibitor Replacement Therapy
(COMPACT).aDepartment of Medicine, Pediatrics and Graduate Studies, Penn State University
Hershey Medical Center, Hershey, Pa
bDepartment of Medicine, University of California San Diego and San Diego VA
Healthcare, La Jolla, Calif
cImmunology Department, Barts Health NHS Trust, The Royal London Hospital,
London, United Kingdom
dDepartment of Biomedical and Clinical Sciences, “L. Sacco” University of Milan/
ASST Fatebenefratelli-Sacco, Milan, Italy
eDepartment of Dermatology, Johannes Gutenberg University, Mainz, Germany
fSt John’s Institute of Dermatology, Tower Wing Guy’s Hospital, London, United
KingdomOBJECTIVE: To assess the long-term safety, occurrence of
angioedema attacks, and use of rescue medication with C1-
INH(SC).
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tional uptitration to optimize prophylaxis (ClinicalTrials.gov
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RESULTS: A total of 126 patients with a monthly attack rate of
4.3 in 3 months before entry in COMPACT were enrolled and
treated for a mean of 1.5 years; 44 patients (34.9%) had more
than 2 years of exposure. Mean steady-state C1-INH functional
activity increased to 66.6% with 60 IU/kg. Incidence of adverse
events was low and similar in both dose groups (11.3 and 8.5
events per patient-year for 40 IU/kg and 60 IU/kg, respectively).
For 40 IU/kg and 60 IU/kg, median annualized attack rates were
1.3 and 1.0, respectively, and median rescue medication use was
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17 Annual Scientific Meeting (June 17-21, Helsinki, Finland) and60 IU/kg for more than 2 years, 19 (83%) were attack-free
during months 25 to 30 of treatment.
CONCLUSIONS: In patients with frequent HAE attacks,
long-term replacement therapy with C1-INH(SC) is safe and
exhibits a substantial and sustained prophylactic effect, with
the vast majority of patients becoming free from debilitating
disease symptoms.  2019 The Authors. Published by Elsevier
Inc. on behalf of the American Academy of Allergy, Asthma &
Immunology. This is an open access article under the CC BY-
NC-ND license (http://creativecommons.org/licenses/by-nc-nd/
4.0/). (J Allergy Clin Immunol Pract 2019;7:1793-802)
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Hereditary angioedema (HAE), types I and II, is a rare
autosomal-dominant genetic disorder that results in a C1 in-
hibitor (C1-INH) protein deficiency or dysfunction.1 It is a
debilitating disease characterized by painful, disfiguring, and
potentially fatal attacks of edema in the subcutaneous tissues of
the face, trunk, and limbs, or the submucosal tissues of the upper
respiratory, gastrointestinal, or genitourinary tracts.2-4at the Hereditary Angioedema Global Conference 2018 Scientific Meeting (May
17-20, Vienna, Austria).
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inflammation via inhibition of the complement system and also
supresses the fibrinolytic system.5-7
Intravenous C1-INH replacement therapy has been used for
many decades and is currently recommended as a first-line
treatment of HAE and for the long-term prophylaxis of
angioedema attacks.8 Routine prophylaxis with intravenous
long-term C1-INH replacement therapy has been used since
2009, based on the outcomes of the CHANGE trial,9 but data
from real-world clinical practice suggest that attacks can occur in
about half the patients with HAE using intravenous C1-INH,
and they often require higher doses than recommended in the
product labeling, which also significantly increases cost.5,10-12 In
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Study design
This study was a multicenter, randomized, parallel-arm, open-
label extension of phase 3 COMPACT, performed in 32 hospitals
across 11 countries (Australia, Canada, Czech Republic, Germany,
Hungary, Israel, Italy, Romania, Spain, the United Kingdom, and
the United States).
The study was done in accordance with the standards of Good
Clinical Practice as defined by the International Council for
Harmonization of Technical Requirements for Registration of
Pharmaceuticals for Human Use, ethical principles that have their
origin in the Declaration of Helsinki, and applicable national and
local regulations. Study protocol and amendments were approved by
independent ethics committees or institutional review boards at all
participating centers before study commencement.
Patients
Patients who completed COMPACT and study treatment-naive
patients were eligible to enroll into the COMPACT extension
study to receive at least 52 weeks of continuous therapy with C1-
INH(SC) 40 or 60 IU/kg twice per week.
Patients were eligible for the study if they were 6 years or older
with a biochemically confirmed diagnosis of type I (C1-INH defi-
ciency) or type II (C1-INH dysfunction) HAE, with C1-INH
functional levels below 50%. Patients who had a history of experi-
encing frequent attacks (at least 4 attacks within 2 consecutive
months) before enrollment into the COMPACT program were
eligible. Patients using oral prophylactic medication were required to
be on a stable regimen and willing to continue this regimen for the
study duration. Key exclusion criteria were any clinical conditions
likely to interfere with the evaluation of the study drug, clinical
history of poor response to C1-INH therapy, and any patient whose
HAE could not be adequately managed by on-demand pharmaco-
logical treatment as assessed by the investigator. All patients, or their
legal guardians, provided written informed consent.
Randomization and masking
Patients either completed the placebo-controlled COMPACT or
were study treatment-naive on enrollment into the open-label
extension study and were randomly assigned 1:1 to receive 40 or
60 IU/kg of C1-INH(SC) twice per week (concentration of 500 IU/
mL). C1-INH(SC) was administered as a single subcutaneous in-
jection either independently (self-administered by the patient) or
with assistance (with the help of a caregiver such as a parent or
guardian). A stratified block randomization scheme was used to
ensure that participants were randomly assigned in a balanced
manner. Participants were stratified by enrollment classification
(study treatment-naive, C1-INH-interrupted, or C1-INH-continu-
ation) to ensure that patients in each of these categories were
balanced between the treatment arms.
Procedures
The study included 2 treatment periods for all patients (Figure 1).
Treatment period 1 constituted a 24-week fixed-dose treatment
period, during which only those patients who were experiencing 12
or more HAE attacks per 4-week evaluation period were eligible for
incremental dose increases of 20 IU/kg up to a maximum dose of 80
IU/kg of C1-INH(SC) at the discretion of the investigator. Treat-
ment period 2 was a 28-week dose-adjustment period wherein pa-
tients experiencing 3 or more attacks within an 8-week evaluation
period were eligible for dose increases to optimize treatmentresponse. A country-specific protocol amendment (July 10, 2015)
added an additional extension period to treatment period 2, which
enabled patients from the United States to continue treatment,
facilitating further long-term data collection for up to an additional
88 weeks. After the last visit in treatment period 2, the extension
period, or any visit resulting in study discontinuation, patients
attended a follow-up assessment visit 2 weeks (3 days) later.
Blood samples were taken at the beginning, middle, and end of
treatment periods 1 and 2 from patients for measurement of C1-
INH functional activity, C1-INH antigen levels, and C4 antigen
levels, and the patient data were summarized for each study group.
C1-INH functional activity was assessed by a validated chromogenic
assay (Berichrom C1-INH, Siemens, Marburg, Germany; normal
range, 70%-130% of the norm), and C1-INH and C4 protein levels
were assessed by nephelometry (N Antiserum to Human C1-INH,
Siemens Healthcare Diagnostics Products GmbH, Marburg, Ger-
many; normal range, 0.18-0.32 mg/mL; C4 reagent, Beckman
Coulter, Inc, Brea, Calif; normal range, 16-38 mg/dL).Outcomes
The primary objective was to determine the long-term safety of
C1-INH(SC). The primary prespecified end points were person-
time incidence rates of related serious adverse events, adverse
events leading to premature discontinuation, adverse events of spe-
cial interest (thromboembolic events and anaphylaxis), HAE attacks
resulting in hospitalization, injection-site reactions graded severe by
the investigator, and the development of neutralizing antieC1-INH
antibodies.
Secondary end points assessed additional safety parameters and
efficacy of C1-INH(SC). Safety parameters included types of adverse
events, suspected drug-related adverse events, and thromboembolic,
anaphylaxis, sepsis, and bacteremia events. Key efficacy end points
included the percentage of patients with a time-normalized attack
frequency of less than 1 attack per 4-week period, and the percentage
of responders (defined as 50% relative reduction in time-
normalized number of attacks during treatment compared with
the time-normalized number of attacks that was used to qualify the
subject for participation in this study). Further efficacy outcomes
included time-normalized number of angioedema attacks, use of
rescue medication, duration of attacks, and number of days when
symptoms of HAE were experienced. The pharmacokinetics and
pharmacodynamics of treatment was an exploratory end point.Statistical analysis
A sample size of 100 patients was planned to complete the study,
providing 95% confidence of observing 1 or more adverse events
with a probability of 3%. Efficacy analyses were based on the
intention-to-treat population by the assigned dose at randomization.
The efficacy end points were summarized descriptively by treatment
and overall. Safety and tolerability were monitored throughout the
study, in addition to vital signs, weight, and laboratory parameters.
Safety analyses were based on all patients in the safety population (all
patients who were randomly assigned and received any study drug).
Patients who were uptitrated from 40 IU/kg to 60 IU/kg were
included in both treatments in the safety analysis. A Safety Data
Monitoring Committee and a Steering Committee provided scien-
tific advice and safety monitoring for the study on an as-needed
basis. This study was registered before enrollment of the first pa-
tient on ClinicalTrials.gov (no. NCT02316353).
FIGURE 1. Trial profile. Patient disposition for the trial and extension periods. Arrows indicate uptitration of dose. AE, Adverse event;MI,
myocardial infarction; TP1, trial period 1; TP2, trial period 2; IU, international units.
TABLE I. Baseline characteristics (ITT population)
Characteristic
C1-INH(SC) 40 IU/kg
(N [ 63)
C1-INH(SC) 60 IU/kg
(N [ 63)
C1-INH(SC) ‡40 IU/kg
(N [ 126)
Age (y)*
Mean  SD 40.8  15.0 40.3  16.3 40.5  15.6
Median (range) 43.0 (8-67) 41.0 (10-72) 41.0 (8-72)
Sex
Women 40 (63) 36 (57) 76 (60)
Men 23 (37) 27 (43) 50 (40)
Race
White 60 (95) 61 (97) 121 (96)
Black or African American 1 (2) 1 (2) 2 (2)
Asian 0 1 (2) 1 (1)
Other 2 (3) 0 (0) 2 (2)
HAE type
Type I 55 (87) 58 (92) 113 (90)
Type II 8 (13) 5 (8) 13 (10)
HAE attacks in the 3 mo before screening
Mean  SD 12.8  8.4 12.7  10.2 12.8  9.3
Median (range) 10.0 (3-37) 9.0 (0-45) 10.0 (0-45)
Use of prophylaxis in the 3 mo before screening†
Overall 7 (23) 8 (23) 15 (24)
C1-INH 6 5 11
Oral prophylaxis (danazol) 1 3 4
ITT, Intention-to-treat.
Data are n (%), mean  SD, or median (range).
*Ten patients were aged <18 y (range, 8-16 y, with 3 patients aged <12 y) and 10 patients were aged 65 y (range, 65-72 y).
†These data include only study treatment-naive patients—40 IU/kg (n ¼ 31), 60 IU/kg (n ¼ 35), 40 IU/kg (n ¼ 62).
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Between December 31, 2014, and May 17, 2016, 131 pa-
tients provided informed consent to participate in this extension
study; 126 were randomly assigned to treatment and received at
least 1 dose of study drug (safety population; Figure 1). All 126
patients were included in the intention-to-treat population. Bothtreatment groups comprised 63 patients each, with 32 (50.8%)
patients previously treated with C1-INH(SC) in each group. Of
the 126 patients in the study, 76 (60.3%) were female and 121
(96.0%) were white. The mean age was 40.5  15.6 years
(range, 8-72 years), with 10 (7.9%) patients younger than 18
years and 3 (2.4%) patients younger than 12 years. Seven
TABLE II. Efficacy end points (ITT population)
Efficacy end points
40 IU/kg
(N [ 63)
60 IU/kg
(N [ 63)
‡40 IU/kg
(N [ 126)
Time-normalized attack rate
No. of attacks/mo, mean  SD 0.4  0.7 0.5  0.9 0.5  0.8
Median no. of attacks/mo (range) 0.1 (0.0 to 3.4) 0.1 (0.0 to 4.0) 0.1 (0.0 to 4.0)
No. of attacks/y, mean  SD 5.4  8.8 5.4  10.3 ND
Median no. of attacks/y (range) 1.3 (0.0 to 40.6) 1.0 (0.0 to 48.0) ND
Time-normalized reduction to <1 attack per month
<1 HAE attack/mo, n (%) 50 (79) 54 (86) 104 (83)
Time-normalized reduction in attack rate from baseline
Mean (95% CI) 6.8 (9.8 to 3.8) 6.8 (10.9 to 2.7) 6.8 (9.3 to 4.3)
Responders (>50% reduction in attacks)
n of responders/N with assessable data 58/62 55/60 113/122
Responder, % (95% Wilson CI)* 94% (85% to 98%) 92% (82% to 96%) 93% (87% to 96%)
Time-normalized use of rescue medication
No. of medications/mo, mean  SD 0.3  0.6 0.3  0.8 0.3  0.7
Median no. of medications/mo (range) 0.02 (0.0 to 3.4) 0.0 (0.0 to 4.5) 0.0 (0.0 to 4.5)
No. of medications/y, mean  SD 3.2  6.9 3.8  9.6 ND
Median no. of medications/y (range) 0.2 (0.0 to 40.6) 0.0 (0.0 to 54.2) ND
Patients with minimal rescue medication use per year, n (%)
<1 rescue medication/y 35 (57) 42 (67) 77 (62)
No rescue medication/y 31 (50) 39 (62) 70 (56)
Time-normalized no. of days of angioedema symptoms per month
Mean  SD 1.3  4.3 0.7  1.4 1.0  3.2
Median (range) 0.2 (0.0 to 30.4) 0.1 (0.0 to 7.2) 0.1 (0.0 to 30.4)
ITT, Intention-to-treat; ND, calculation not done.
Data are n (%), mean  SD, or median (range), unless noted otherwise.
*The difference between C1-INH(SC) doses is assessed using Wilson asymptotic confidence limits for the difference in percentages.
J ALLERGY CLIN IMMUNOL PRACT
JULY/AUGUST 2019
1798 CRAIG ETAL(11.1%) patients were uptitrated from 40 IU/kg to 60 IU/kg and
were included in the safety population for both treatment
groups. Of these, 2 (28.6%) patients were further uptitrated to
80 IU/kg. In addition, 2 (3.2%) patients randomly assigned to
receive 60 IU/kg were uptitrated to 80 IU/kg during the
extension period. Events recorded in the 4 (3.2%) patients
uptitrated to 80 IU/kg were included in the greater than or equal
to 40 IU/kg analyses.
At database lock on December 20, 2017, 110 (87.3%) pa-
tients had completed the study. The baseline characteristics of
the safety population are presented in Table I. Before entry into
either COMPACT or COMPACT long-term safety, the median
prestudy 3-month attack rate was 9 (60 IU/kg group) and 10 (40
IU/kg group) attacks, respectively. Prophylactic treatment for
HAE (either attenuated androgen [n ¼ 4] or C1-INH replace-
ment [n ¼ 11]) was used by 8 of 35 (22.9%) and 7 of 31
(22.6%) study treatment-naive patients in the 60 IU/kg and 40
IU/kg groups, respectively. No notable differences were observed
between the baseline characteristics of the 60 IU/kg and 40 IU/
kg study groups.
Of the 15 (11.9%) patients who discontinued treatment
before week 53, 9 (7.1%) patients discontinued during treatment
period 1 (4 of 63 [6.3%] and 5 of 63 [7.9%] patients in the 60
IU/kg and 40 IU/kg groups, respectively) and 6 (4.8%) patients
discontinued during treatment period 2 (3 patients in each
group). In addition, 1 (1.6%) patient from the 60 IU/kg group
discontinued during the extension period (Figure 1).The duration of exposure in the safety population ranged from
2 to 140 weeks (median, 52.6 weeks; mean, 75.5  39.5 weeks).
In total, 745 angioedema attacks were reported by 126 patients
across both groups over an observation period of up to 2.7 years,
resulting in median attack rates of 0.09 and 0.11 attacks per
month (corresponding to 1.0 and 1.3 attacks per year) for patients
in the 60 IU/kg and 40 IU/kg groups, respectively. Thirty-six
(57.1%) patients in the 60 IU/kg group and 31 (49.2%) pa-
tients in the 40 IU/kg group reported no or mild attacks,
respectively. Seventeen (27.0%) patients in the 60 IU/kg group
and 12 (19.0%) patients in the 40 IU/kg group reported at least 1
severe attack. In the 60 IU/kg group, 31 (49.2%) patients had an
attack frequency of less than 1 attack per year compared with 27
(43.5%) patients in the 40 IU/kg group. Out of 122 patients, 113
(92.6%) were defined as treatment responders (ie, 50% reduc-
tion in the time-normalized number of HAE attacks; Table II).
Uptitration by 20 IU/kg increments lowered the rate of attacks in
7 (77.8%) of 9 patients who continued to experience frequent
attacks under their randomly assigned dose; the attack rate was
unchanged in the remaining 2 patients.
In the 60 IU/kg group, 61.7% (229 of 371 events) of
angioedema attacks were treated, and in the 40 IU/kg group,
51.3% (192 of 374 events) of angioedema attacks were treated.
Most patients with treated attacks were managed using a single
rescue medication. In the 60 IU/kg and 40 IU/kg groups, 66.7%
and 56.5%, respectively, used less than 1 rescue medication per
year. Post hoc analysis of annualized rescue medication use showed
FIGURE 2. Percentage of patients with more than 2 years’ exposure who were attack-free by 6-month time window (A) and who did not
use any rescue medication (B), by 6-month time window. IU, International units.
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patients receiving 40 IU/kg used no rescue medication (Table II).
The median number of days with angioedema symptoms
experienced per month was 0.12 and 0.18 day for the 60 IU/kg
and 40 IU/kg treatment groups, respectively.
In a post hoc analysis of 23 and 21 patients exposed to 60 IU/
kg and 40 IU/kg C1-INH(SC), respectively, for more than 2
years, the percentage of patients who were completely attack-free
within the last period of observation available for all patients
(months 25-30) was numerically higher in the 60 IU/kg group
than in the 40 IU/kg group (Figure 2, A). In the 60 IU/kg dose
group with more than 2 years’ exposure, 19 (82.6%) of 23 pa-
tients were completely attack-free and 20 (87.0%) of 23 patients
did not use any rescue medication in months 25 to 30 of their
observation period (Figure 2, A and B).Before prophylactic treatment, the mean C1-INH functional
activity at baseline was 28.3%  8.0% and 30.4%  14.6% in
the 60 IU/kg and 40 IU/kg treatment groups, respectively. The
mean steady-state C1-INH functional activity increased with
treatment to 66.6%  34.9% with 60 IU/kg and 52.0% 
17.2% with 40 IU/kg at the end of study (Figure 3, A and B).
The mean concentration of C4 antigen at baseline was below
normal levels,15 at 9.1  5.0 mg/dL in the 60 IU/kg group and
10.5  5.4 mg/dL in the 40 IU/kg group. The mean concen-
tration of C4 antigen increased to close to normal levels with 60
IU/kg (16.3  6.6 mg/dL) and to 14.8  5.9 mg/dL with 40
IU/kg at the end of the study (Figure 3, C).
Similar adverse event profiles were reported in both treatment
arms of the study, with an event rate of 8.5 and 11.3 adverse
events per patient-year of exposure to 60 IU/kg and 40 IU/kg C1-
FIGURE 3. Pharmacokinetic and pharmacodynamic findings over the course of the study. Mean (dots) and SD (vertical lines) of C1-INH
functional activity (A), C1-INH protein (B), and C4 protein (C). The gray boxed area indicates the extended study period. LLN, Lower limit
of normal (LLN taken from Tarzi et al15). IU, International units.
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adverse events in both treatment groups were nasopharyngitis,
upper respiratory tract infections, headache, and localized
injection-site reactions (see Table E1 in this article’s Online Re-
pository at www.jaci-inpractice.org). No dose-dependent safety
concerns were identified.
The most frequently observed adverse events were injection-
site reactions. Overall incidence rates of injection-site reactions
were 0.06 and 0.08 events per injection for 60 IU/kg and 40 IU/
kg, respectively, but 4 patients, who were administered approx-
imately 3% of all injections delivered during the study,
accounted for more than 50.0% (675 of 1251 events) of allsolicited adverse events. Most solicited adverse events occurred
within 24 hours after injection (1180 of 1251 events), were mild
in severity (1234 of 1251 events), and were resolved within 24
hours of appearance (955 of 1251 events).
Twelve serious adverse events were experienced by 9 (7.1%)
patients, 1 of which (myocardial infarction, unrelated to treat-
ment) led to study discontinuation (details provided in footnote
of Table III). Most serious adverse events were moderate or se-
vere in intensity and resolved. None was deemed to be related to
the study drug.
Four adverse events led to study discontinuation, including
the unrelated serious adverse event of myocardial infarction. Four
TABLE III. AEs (safety population)
40 IU/kg (N [ 63) 60 IU/kg (N [ 70)* ‡40 IU/kg (N [ 126)
n (%)
Events
(events/patient-year) n (%)
Events
(events/patient-year) n (%)
Events
(events/patient-year)
AEs 56 (89) 948 (11.3) 58 (83) 849 (8.5) 108 (86) 1811 (9.7)
Mild 49 (78) 839 (10.0) 51 (73) 725 (7.3) 97 (77) 1572 (8.4)
Moderate 34 (54) 99 (1.2) 36 (51) 116 (1.2) 69 (55) 218 (1.2)
Severe 8 (13) 10 (0.1) 7 (10) 8 (0.1) 16 (13) 21 (0.11)
Treatment-related AEs 36 (57) 697 (8.3) 32 (46) 556 (5.6) 66 (52) 1257 (6.7)
AEs leading to discontinuation† 1 (2) 1 (0.0) 3 (4) 3 (0.0) 4 (3) 4 (0.0)
SAEsz 4 (6) 5 (0.1) 5 (7) 6 (0.1) 9 (7) 12 (0.1)
Treatment-related SAEs — 0 — 0 — 0
SAEs leading to discontinuation — 0 1 (1) 1 (0.0) 1 (1) 1 (0.0)
Injection-site reactionsx 35 (56) 692 (8.2) 32 (46) 554 (5.6) 65 (52) 1251 (6.7)
Unsolicited AEs 50 (79) 256 (3.1) 56 (80) 295 (3.0) 100 (79) 560 (3.0)
Treatment-related unsolicited AEs 4 (6) 5 (0.1) 3 (4) 4 (0.0) 7 (6) 9 (0.1)
AE, Adverse event; SAE, serious adverse event.
Data are n (%), unless noted otherwise.
*Seven patients who were uptitrated from 40 IU/kg to 60 IU/kg were included in both treatment arms in the safety population. Therefore, the safety population included 63
subjects in the 40 IU/kg treatment arm and 70 subjects in the 60 IU/kg treatment arm.
†Nonserious AEs leading to discontinuation were headache, myalgia, and arthralgia.
zNontreatment-related SAEs were reported in 9 patients (cholelithiasis, diffuse large B-cell lymphoma, contusion after fall, diplopia, acute myocardial infarction, hospitalization
due to dehydration and hypokalemia, dizziness and chest pain, bronchitis, pneumonia, and laryngeal attack resulting in hospital admission).
xInjection-site reactions included bruising, erythema, pain, swelling, edema, hemorrhage, and induration.
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having received a total exposure of 15 to 85 doses of C1-
INH(SC), inclusive of administrations throughout the first
trimester until pregnancy was detected. All women delivered
healthy babies with no fetal abnormalities.
Aside from the single investigator-determined unrelated
serious adverse event of myocardial infarction reported, no
thromboembolic events were recorded during the study. No
cases of anaphylaxis were reported. No neutralizing antibodies to
C1-INH were observed at baseline or at any postbaseline visit.
No seropositive events for HIV, hepatitis B virus, or hepatitis C
virus were recorded. No deaths occurred during the study period.DISCUSSION
The open-label extension COMPACT is the first and largest
long-term study to investigate the safety and prophylactic effect of
twice-weeklyC1-INH(SC) over an extended period in patientswith
frequent HAE attacks, including children as young as 8 years. Pa-
tients were exposed to C1-INH(SC) for a mean of 1.5 years; 23
patients were exposed to 60 IU/kg for more than 2 years.
In this study, both doses of C1-INH(SC) were well tolerated
and adverse events were infrequent and generally mild to
moderate in intensity. The most common adverse effects were
injection-site reactions related to the subcutaneous adminis-
tration, a finding that is consistent with data from the placebo-
controlled COMPACT.13 The patients with HAE studied were
severely affected by their disease, and reported a median of 10
attacks during the 3 months, and a mean of 4.3 attacks per
month, before study entry, despite almost one-quarter of study
treatment-naive patients already receiving a prophylaxis
regimen. Over the course of the study, the median annualized
attack rate was reduced to 1.0 attack per year and the per-
centage of patients achieving an attack rate of less than 1 attack
per month was 86% in the 60 IU/kg group. Most angioedemaattacks experienced by patients in the study were mild to
moderate. As anticipated, the use of rescue medication was very
low, with a median annualized usage rate of 0.0 uses per year;
62.0% of patients did not use any rescue medication within 1
year in the 60 IU/kg treatment arm. Consistent with the
placebo-controlled COMPACT,10 the approved and recom-
mended dosing of 60 IU/kg shows a numerically better
prophylactic effect than does the 40 IU/kg dose.13 This finding
was evident as assessed by multiple efficacy end points,
including the need for uptitration to the 60 IU/kg dose, which
was necessary in 7 (11.1%) of 63 patients in the 40 IU/kg arm,
but only 2 (3.2%) of 63 patients required uptitration from the
60 IU/kg dose to 80 IU/kg.
C1-INH(SC) treatment resulted in a high number of attack-
free patients by the end of the study. In patients treated for more
than 2 years with the 60 IU/kg dose, 20 (87.0%) of 23 patients
no longer used any rescue medication, and 19 (82.6%) achieved
an attack-free status in the observation period from month 25 to
30. There was no clinical evidence of tolerance induction or
tachyphylaxis, as the proportion of attack-free patients increased
over time. As seen in the pivotal COMPACT,13 the 60 IU/kg
dose achieved consistently higher C1-INH functional activity
levels in patients, which were closer to the lower limit of normal
and were more likely to normalize C4 protein levels than the 40
IU/kg dose. These data support previous findings of an inverse
relationship of functional C1-INH activity levels and risk of an
angioedema attack.16
HAE impairs health-related quality of life through anxiety,
loss of work productivity, and activity impairment. The unpre-
dictability of angioedema attacks and the fear of asphyxiation
make anxiety a particular burden.17,18 On the basis of
COMPACT,13 we can say that C1-INH(SC) improves several
health-related quality-of-life impairments, particularly anxiety
and work productivity, compared with on-demand treatment
alone.17 Further explorations of the long-term health-related
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will be the subject of ongoing research.
During the course of our study, 4 patients became pregnant
and received treatment until the pregnancy was identified;
treatment was discontinued according to protocol. All women
delivered healthy babies. Human C1-INH is the only recom-
mended treatment for prophylaxis of angioedema attacks in
pregnant or breast-feeding women.19-21 Because C1-INH(SC)
became available only recently, clinical experience in special
populations is sparse and further data in special populations may
need to be collected. Nonetheless, the preparation of C1-INH
used in this study is very similar to the preparation used for
more than 30 years in the European Union, varying only in route
of administration and concentration.
A limitation of this study is the inclusion of relatively low
numbers of patients with specific comorbidities and other cir-
cumstances that may affect the disease. HAE is often diagnosed
in childhood and is present throughout a patient’s lifetime, so
although this long-term study extends the evidence base
beyond the 16-week randomized study period, even longer-
term evidence may need to be collected. Although pediatric
and elderly patients participated in this study, the number of
patients was small to examine any effects specific to these pa-
tient subgroups. Furthermore, very rare treatment-related
adverse events that may occur cannot be ruled out. In addi-
tion, the study could not fully address questions on the use of
individualized dosing to optimize treatment response, because
only few subjects had a dose uptitration and dose downtitration
was not attempted.
In conclusion, this long-term extension study confirms
previous results of the placebo-controlled COMPACT13 and
demonstrates durable efficacy with a sustained reduction in HAE
attacks, symptoms, and the need for rescue medication. Long-
term subcutaneous C1-INH replacement therapy provides a
safe and sustained prophylactic treatment effect that allows
patients to become free of HAE disease symptoms.
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Israel: Tel Hashomer: A. Reshef and M. Kidon; Tel Aviv: S.
Kivity, L. Kadar, and S. Benor
Italy: Milano: M. Cicardi, E. Bonanni, M. Wu, A. Zanichelli,
and M. Mansi; Catania: S. Neri, A. Rizzotto, F. Giardino, and F.
Fidone
Romania: Cluj: I. Crisan, M. Varga, M. Iftene, and I.D.
Badiu-Tisa
Spain: Madrid: T. Caballero, R. Cabañas, M. Pedrosa, D.
Rivero-Paparoni, C. Gómez-Traseira, A. Alvez, E. Phillips, M.L.
Baeza, A. Prieto, and J. Zubeldia; Valencia: M.D. Hernandez,
E. Ibanez, and R. Almero
United Kingdom: London: H. Longhurst, M. Buckland, S.
Grigoriadou, A. Manson, N. Yeatman, J. Laffan, I. Nasr, R.
Ghurye, and T. Rehman
United States:Hershey: T. Craig, C. Schaeffer, G. Ghaffari, T.
Kelbel, V. Reddy, L. Buyantseva, C. Mende, J. Jose, and T.
Novchicht; Chevy Chase: H.H. Li, M. Scarupa, A. Economides,
M. White, M. Kaliner, C. Ward, S. Shaikh, T. Johnson, L.
Kosh, and P. Dauphin; Lake Oswego: J. Baker, S. Persons, A.
Newman, and M.J. Noonan; Dallas: W.R. Lumry, K.P. Poarch,
J. Tucker, D. Aguilar, and D. Noth; Cincinnati: J. Bernstein, D.
Bernstein, and S. Evans; Tulsa: I. Hussain, M. Crawford, S.D.
McGuckin, J.R. McCollum, B. Bradley, C. Wagner, and A.
Cartwright; Birmingham: J. Bonner, J. Anderson, W. Soong,
M. Sikora, M. Lemke, P. Luthin, B. Youngblood, and E.
DeBerry; Richmond: L.B. Schwartz, E. Gilbert, W. Zhao, B.
Ward, A. Alvarez, S. Kumar, and E. Akl; Walnut Creek: J. Ja-
cobs, J. Curl, K. Silva, T. Mostofi, and N. Schultz; Scottsdale:
M.E. Manning, A. Davis, and J. Nelson; Orange: D.S. Levy; La
Jolla: M. Riedl, B. Zuraw, and S.C. Christiansen
TABLE E1. Adverse events reported in 5% of patients (safety population)
MedDRA preferred term
40 IU/kg
(N [ 63)
60 IU/kg
(N [ 70)
‡40 IU/kg
(N [ 126)
n (%)*
Events
(events/exposure-year)† n (%)*
Events
(events/exposure-year)† n (%)*
Events
(events/exposure-year)†
Nasopharyngitis 12 (19.0) 23 (0.27) 21 (30.0) 36 (0.36) 32 (25.4) 61 (0.33)
Injection-site pain 17 (27.0) 211 (2.52) 10 (14.3) 51 (0.51) 26 (20.6) 262 (1.40)
Injection-site erythema 10 (15.9) 45 (0.54) 12 (17.1) 331 (3.32) 21 (16.7) 376 (2.01)
Headache 10 (15.9) 22 (0.26) 10 (14.3) 19 (0.19) 20 (15.9) 42 (0.22)
Injection-site bruising 9 (14.3) 56 (0.67) 7 (10.0) 22 (0.22) 17 (13.5) 83 (0.44)
Upper respiratory tract infection 8 (12.7) 10 (0.12) 8 (11.4) 10 (0.10) 16 (12.7) 20 (0.11)
Injection-site reaction 5 (7.9) 75 (0.89) 8 (11.4) 72 (0.72) 12 (9.5) 147 (0.79)
Arthralgia 6 (9.5) 6 (0.07) 5 (7.1) 5 (0.05) 11 (8.7) 11 (0.06)
Back pain 7 (11.1) 7 (0.08) 3 (4.3) 4 (0.04) 10 (7.9) 11 (0.06)
Bronchitis 7 (11.1) 7 (0.08) 2 (2.9) 2 (0.02) 9 (7.1) 9 (0.05)
Injection-site hematoma 6 (9.5) 11 (0.13) 4 (5.7) 12 (0.12) 9 (7.1) 23 (0.12)
Nausea 5 (7.9) 10 (0.12) 4 (5.7) 14 (0.14) 9 (7.1) 24 (0.13)
Urinary tract infection 3 (4.8) 4 (0.05) 6 (8.6) 6 (0.06) 9 (7.1) 10 (0.05)
Sinusitis 4 (6.3) 4 (0.05) 4 (5.7) 7 (0.07) 8 (6.3) 11 (0.06)
Diarrhea 4 (6.3) 12 (0.14) 2 (2.9) 2 (0.02) 7 (5.6) 15 (0.08)
Injection-site induration 4 (6.3) 19 (0.23) 3 (4.3) 4 (0.04) 7 (5.6) 23 (0.12)
Contusion 5 (7.9) 5 (0.06) 1 (1.4) 1 (0.01) 6 (4.8) 6 (0.03)
Injection-site swelling 4 (6.3) 19 (0.23) 2 (2.9) 2 (0.02) 6 (4.8) 21 (0.11)
Myalgia 4 (6.3) 6 (0.07) 1 (1.4) 6 (0.06) 5 (4.0) 12 (0.06)
Toothache 1 (1.6) 1 (0.01) 4 (5.7) 4 (0.04) 5 (4.0) 5 (0.03)
Migraine 4 (6.3) 8 (0.10) — 0 (0.00) 4 (3.2) 8 (0.04)
*Percentage of patients who experienced an adverse event (%) ¼ (the number of patients with 1 event [n])/(the number of patients receiving the corresponding treatment [N]).
†Rate/y ¼ (the total number of events documented during the respective treatment)/(the total duration of exposure [d] to the respective treatment)/(365.25 d).
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